SOURCE: Herborium Group, Inc.

December 09, 2010 09:51 ET

Herborium Announces the New International Distribution

SADDLE BROOK, NJ--(Marketwire - December 9, 2010) - Herborium Group, Inc., (PINKSHEETS: HBRM), a Botanical Therapeutics™ company, today announced that it is partnering with the retail division of the major Portal Technology provider, Adrecom, to distribute its unique botanical therapeutic, AcnEase®, for Acne and Rosacea ( in Israel with expected $500,000 plus in revenues over next 36 months. This partnership furthers our efforts to become the worldwide leader in Natural Acne Treatment and Preventative Therapy.

Israel is a very attractive market for AcnEase. Its population of 24 million have maintained the highest per-capita income in the region (close to $29,000) and only 6.2% unemployment rate. In addition, according to the Euromonitor International, Israel maintains a 4% yearly growth, and 2009 and 2010 witnessed a continuous increase in sales of health supplements and nutraceuticals, "as awareness of its positive benefits increases among Israeli consumers." Health supplements in Israel represent a large potential for near-term growth as 30% of households in Israel consume natural medicinal products and market penetration rates are rising.

"The opportunity for AcnEase sales in Israel is considerable," commented Dr. Agnes Olszewski, Herborium's president and chief executive officer. "We anticipate meeting the regulatory requirements necessary to enter the market within the next three months. The partners will commit the funds necessary to meet those requirements as well as the associated marketing costs. AcnEase is especially attractive to Israeli consumers as it is not only efficacious and all natural, but also suitable for all types of skin pigmentation."

Herborium expects to enter the market by the end of the second quarter of 2011 and market projection for the first 12 months call for sales of between $100,000 to $150,000, with $300,000 projected within 24-36 months. The arrangement is not exclusive until sales performance milestones are met.

The new international distribution arrangements are but one example of Herborium's "Road-to-Market" Strategy calling for revenues projections of $7.5 Million, as detailed ("Road-to-Market" Strategy), and with an ultimate goal to eventually capturing 1% of the Global Natural and Alternative Treatments Market.

About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanically based medicinal products to consumers and healthcare professionals. The Company's business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit and

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

Contact Information

  • Company Contact:
    Steve Haag
    Investor Relations
    (832) 413-6206